Home » Stocks » Prevail Therapeutics

Prevail Therapeutics Inc. (PRVL)

Stock Price: $15.24 USD 0.06 (0.40%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 521.23M
Revenue (ttm) n/a
Net Income (ttm) -71.82M
Shares Out 34.20M
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $15.24
Previous Close $15.18
Change ($) 0.06
Change (%) 0.40%
Day's Open 15.34
Day's Range 15.08 - 15.59
Day's Volume 96,270
52-Week Range 7.41 - 19.96

More Stats

Market Cap 521.23M
Enterprise Value 382.51M
Earnings Date (est) Aug 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.20M
Float 9.99M
EPS (basic) -2.3
EPS (diluted) -2.65
FCF / Share -1.92
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.88M
Short Ratio 6.70
Short % of Float 11.42%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.55
Revenue n/a
Operating Income -74.58M
Net Income -71.82M
Free Cash Flow -63.84M
Net Cash 138.72M
Net Cash / Share 4.06
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.92%
ROE -57.40%
ROIC -394.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(44.36% upside)
Current: 15.24
Target: 22.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-65.80-18.72
Net Income-63.19-19.09
Shares Outstanding28.495.15
Earnings Per Share-2.22-3.71
Operating Cash Flow-55.75-14.01
Capital Expenditures-2.14-0.63
Free Cash Flow-57.89-14.64
Cash & Equivalents16863.11
Total Debt11.278.87
Net Cash / Debt15754.24
Book Value165-18.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Prevail Therapeutics Inc.
Country United States
Employees 62
CEO Asa Abeliovich

Stock Information

Ticker Symbol PRVL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRVL


Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.